MicroPort Scientific Corporation (00853) Announces Endovastec’s 2025 Unaudited Financial Results

Bulletin Express02-27

MicroPort Scientific Corporation (00853) reported key unaudited financial figures for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) for the twelve months ended 31 December 2025. Endovastec is 40.32% owned by MicroPort Scientific Corporation, and its results are included in the consolidated statements.

\n\nEndovastec recorded revenue of RMB 1.35 billion in 2025, representing an 11.96% increase compared to RMB 1.21 billion in 2024. The profit amount was RMB 653.37 million, reflecting a slight rise of 0.18% over RMB 652.19 million in the prior period. Net profit attributable to Endovastec’s equity owners reached RMB 563.21 million, a 12.17% growth year-on-year.

\n\nAs of 31 December 2025, Endovastec’s total assets were RMB 4.64 billion, up 8.13% from RMB 4.29 billion at the end of 2024. Total equity attributable to Endovastec’s equity owners was RMB 4.08 billion, representing a 7.48% increase from RMB 3.79 billion as of the same time last year.

\n\nAccording to the announcement, the above data is prepared under PRC accounting standards, specific only to Endovastec. Shareholders and investors are advised that it does not present a full picture of the group’s overall operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175744071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175744071","market":"hk","top_or_hot":-1,"title":"MicroPort Scientific Corporation (00853) Announces Endovastec’s 2025 Unaudited Financial Results","media":"Bulletin Express","content":"<p>MicroPort Scientific Corporation (00853) reported key unaudited financial figures for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) for the twelve months ended 31 December 2025. Endovastec is 40.32% owned by MicroPort Scientific Corporation, and its results are included in the consolidated statements.</p>\n<p>\\n\\nEndovastec recorded revenue of RMB 1.35 billion in 2025, representing an 11.96% increase compared to RMB 1.21 billion in 2024. The profit amount was RMB 653.37 million, reflecting a slight rise of 0.18% over RMB 652.19 million in the prior period. Net profit attributable to Endovastec’s equity owners reached RMB 563.21 million, a 12.17% growth year-on-year.</p>\n<p>\\n\\nAs of 31 December 2025, Endovastec’s total assets were RMB 4.64 billion, up 8.13% from RMB 4.29 billion at the end of 2024. Total equity attributable to Endovastec’s equity owners was RMB 4.08 billion, representing a 7.48% increase from RMB 3.79 billion as of the same time last year.</p>\n<p>\\n\\nAccording to the announcement, the above data is prepared under PRC accounting standards, specific only to Endovastec. Shareholders and investors are advised that it does not present a full picture of the group’s overall operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MicroPort Scientific Corporation (00853) Announces Endovastec’s 2025 Unaudited Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroPort Scientific Corporation (00853) Announces Endovastec’s 2025 Unaudited Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-27 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MicroPort Scientific Corporation (00853) reported key unaudited financial figures for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) for the twelve months ended 31 December 2025. Endovastec is 40.32% owned by MicroPort Scientific Corporation, and its results are included in the consolidated statements.</p>\n<p>\\n\\nEndovastec recorded revenue of RMB 1.35 billion in 2025, representing an 11.96% increase compared to RMB 1.21 billion in 2024. The profit amount was RMB 653.37 million, reflecting a slight rise of 0.18% over RMB 652.19 million in the prior period. Net profit attributable to Endovastec’s equity owners reached RMB 563.21 million, a 12.17% growth year-on-year.</p>\n<p>\\n\\nAs of 31 December 2025, Endovastec’s total assets were RMB 4.64 billion, up 8.13% from RMB 4.29 billion at the end of 2024. Total equity attributable to Endovastec’s equity owners was RMB 4.08 billion, representing a 7.48% increase from RMB 3.79 billion as of the same time last year.</p>\n<p>\\n\\nAccording to the announcement, the above data is prepared under PRC accounting standards, specific only to Endovastec. Shareholders and investors are advised that it does not present a full picture of the group’s overall operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00853","symbol_name":"微创医疗","start_time":0,"source_url":"","article_id":"1175744071","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175744071","pubTimestamp":1772194228,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"MicroPort Scientific Corporation (00853) reported key unaudited financial figures for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) for the twelve months ended 31 December...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00853":"微创医疗"},"translate_title":"微创医疗(00853)公布Endovastec 2025年未经审核财务业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1},"content_text":"MicroPort Scientific Corporation (00853) reported key unaudited financial figures for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) for the twelve months ended 31 December 2025. Endovastec is 40.32% owned by MicroPort Scientific Corporation, and its results are included in the consolidated statements.\n\\n\\nEndovastec recorded revenue of RMB 1.35 billion in 2025, representing an 11.96% increase compared to RMB 1.21 billion in 2024. The profit amount was RMB 653.37 million, reflecting a slight rise of 0.18% over RMB 652.19 million in the prior period. Net profit attributable to Endovastec’s equity owners reached RMB 563.21 million, a 12.17% growth year-on-year.\n\\n\\nAs of 31 December 2025, Endovastec’s total assets were RMB 4.64 billion, up 8.13% from RMB 4.29 billion at the end of 2024. Total equity attributable to Endovastec’s equity owners was RMB 4.08 billion, representing a 7.48% increase from RMB 3.79 billion as of the same time last year.\n\\n\\nAccording to the announcement, the above data is prepared under PRC accounting standards, specific only to Endovastec. Shareholders and investors are advised that it does not present a full picture of the group’s overall operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175744071","isCrawlerRequest":true}